On January 9, 2025, Prudentia Sciences, an AI-powered technology platform for life sciences, emerged from stealth supported by $7 million in funding. Google Ventures led the financing with participation from Iaso Ventures and Virtue. Wilson Sonsini Goodrich & Rosati advised Prudentia Sciences on the transaction.

Prudentia Sciences' platform aims to help biopharma companies accelerate drug pipelines and maximize return on investment. It provides rapid asset diligence and valuation capabilities, and helps investors make data-driven decisions for portfolio strategy planning. The company intends to use the funds to accelerate product development and deployment.

The Wilson Sonsini team that advised Prudentia Sciences includes Mark Solakian, Tamara Labanowski, and Aaron Gordon.

For more information, please see Prudentia Sciences' news release. Additional coverage can be found on Endpoints News.